Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis.

Jacob E OllechInessa NormatovNoam PelegSushila R DalalJoel PekowDejan MicicRussel D CohenDavid T RubinAtsushi Sakuraba

Published in: International journal of colorectal disease (2020)

A significant proportion of patients with severe colitis failing IV steroids responded to induction therapy with CT-P13. Colectomy-free survival rates were similar to previous randomized trials using originator infliximab as induction therapy in severe steroid-refractory colitis.

Keyphrases

ulcerative colitis
free survival
early onset
computed tomography
image quality
contrast enhanced
drug induced
smoking cessation